Last reviewed · How we verify

Anoxia due to high altitude — Treatment Landscape & Competitive Intelligence

Anoxia due to high altitude (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anoxia due to high altitude, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Diamox ACETAZOLAMIDE Teva Carbonic Anhydrase Inhibitor [EPC] Carbonic anhydrase 1953-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Teva · 1 drug in Anoxia due to high altitude

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anoxia due to high altitude:

Cite this brief

Drug Landscape (2026). Anoxia due to high altitude — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anoxia-due-to-high-altitude. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing